Does Medicare Advantage Cover Repatha (Evolocumab)?

How Medicare Advantage Classifies Repatha on Formulary

Most Medicare Advantage plans with Part D benefits place Repatha (evolocumab 140 mg/mL prefilled syringe or autoinjector) on Specialty Tier 5. This classification carries the highest cost-sharing, typically 25% to 33% coinsurance after the deductible phase. Plans operated by UnitedHealthcare, Humana, Aetna, Cigna, and regional carriers follow CMS formulary guidelines but retain flexibility in tier placement and utilization management tools [1].

CMS requires all Part D sponsors to cover at least one PCSK9 inhibitor. Because only two branded PCSK9 inhibitors exist (evolocumab and alirocumab), most formularies include both, though preferred status may differ by plan year. The 2025 CMS formulary reference file shows evolocumab listed on 94% of standalone Part D and Medicare Advantage Prescription Drug (MA-PD) formularies reviewed by the Medicare Payment Advisory Commission [2].

Specialty tier drugs under Part D are exempt from the standard tiering exceptions process. A beneficiary cannot request a tier reduction for Repatha the way they could for a Tier 3 or Tier 4 drug. The only path to lower out-of-pocket cost is through the catastrophic coverage phase, where Medicare pays 80% and the plan pays 15%, leaving the patient responsible for 5% of drug costs or a small copayment.

Prior Authorization Criteria for Repatha Under Medicare Advantage

Every major Medicare Advantage carrier requires prior authorization before dispensing Repatha. The criteria are drawn from CMS model coverage determinations and the drug's FDA-approved labeling [3].

Standard prior authorization requirements include a confirmed diagnosis of HeFH, HoFH, or clinical ASCVD (defined as history of myocardial infarction, stroke, or peripheral arterial disease). The prescribing physician must document that the patient's LDL-C remains above goal despite maximally tolerated statin therapy. Most plans define "maximally tolerated" as the highest dose the patient can take without intolerable side effects, or documented statin intolerance confirmed by rechallenge or CK elevation.

Specific documentation typically required:

• Fasting lipid panel within 30 to 90 days showing LDL-C above 70 mg/dL (for ASCVD) or above 100 mg/dL (for primary prevention with HeFH)
• List of all lipid-lowering agents tried, with dates, doses, and reasons for discontinuation
• Prescriber attestation that the patient is on concurrent maximally tolerated statin or is statin-intolerant
• For HeFH: genetic confirmation or Simon Broome / Dutch Lipid Network clinical criteria score

Authorization periods run 6 to 12 months depending on the plan. Reauthorization requires updated lipid values showing LDL-C reduction of at least 30% from pre-treatment baseline, confirming the patient is responding to therapy.

Step Therapy Requirements Before Repatha Approval

Step therapy is the most common barrier to Repatha access on Medicare Advantage. Plans require failure of, or intolerance to, sequential therapies before authorizing a PCSK9 inhibitor [4].

The typical step sequence mandated by Medicare Advantage carriers follows a predictable pattern. Step one requires trial of a high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for a minimum of 8 to 12 weeks. Step two adds ezetimibe 10 mg to the statin regimen for another 8 to 12 weeks. Only after documented failure of both steps (LDL-C still above goal) does the plan consider Repatha.

Some plans add a third step requiring trial of bempedoic acid (Nexletol) or the bempedoic acid/ezetimibe combination (Nexlizet) before PCSK9 inhibitor approval. This additional requirement became more common in plan year 2025 after bempedoic acid's CLEAR Outcomes trial demonstrated a 13% reduction in major cardiovascular events in statin-intolerant patients (N=13,970) [5].

For patients with documented statin intolerance (defined by the National Lipid Association as inability to tolerate two or more statins at any dose), plans may waive the statin step but still require ezetimibe trial. Complete statin intolerance must be documented with specific adverse effects and dates of each statin trial.

What Repatha Costs on Medicare Advantage After Approval

Once approved, out-of-pocket costs depend on which Part D coverage phase the beneficiary is in. Repatha's wholesale acquisition cost is approximately $580 per month ($6,960 annually) [6].

During the initial coverage phase (after the $590 deductible in 2025), specialty tier coinsurance of 25% means the patient pays roughly $145 per month. Under the Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective January 2025), beneficiaries hit the cap within approximately 14 months of Repatha fills. After reaching the cap, cost-sharing drops to $0 for the remainder of the plan year [7].

The $2,000 cap represents a major change for PCSK9 inhibitor access. Before 2025, patients in the coverage gap ("donut hole") faced 25% coinsurance on a $580 drug with no annual ceiling. The Congressional Budget Office estimated that 1.4 million Medicare beneficiaries on specialty drugs would benefit from the cap in its first year.

Amgen's Repatha patient assistance program (RPAP) does provide free drug to Medicare beneficiaries who meet income criteria (household income at or below 300% of the federal poverty level). This is distinct from commercial copay cards, which cannot be used with any federal healthcare program due to the Anti-Kickback Statute, 42 U.S.C. § 1320a-7b.

The Clinical Evidence Behind Medicare's Coverage Decision

Medicare coverage of PCSK9 inhibitors rests primarily on the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), published in the New England Journal of Medicine in 2017. FOURIER enrolled 27,564 patients with established ASCVD and LDL-C of 70 mg/dL or higher despite statin therapy [1].

At a median follow-up of 2.2 years, evolocumab reduced the primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001). The key secondary endpoint (cardiovascular death, MI, or stroke) was reduced by 20% (HR 0.80 to 95% CI 0.73 to 0.88, P<0.001). Median LDL-C fell from 92 mg/dL to 30 mg/dL in the evolocumab group [1].

Dr. Marc Sabatine, the FOURIER trial's principal investigator at Brigham and Women's Hospital, stated: "These findings establish that inhibiting PCSK9 with evolocumab on top of statin therapy reduces cardiovascular events, consistent with the expected benefit for the magnitude of LDL lowering achieved" [1].

The 2018 AHA/ACC Cholesterol Clinical Practice Guideline incorporated FOURIER's results, recommending PCSK9 inhibitors as a "reasonable" addition for patients with ASCVD at very high risk whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe (Class IIa recommendation, Level of Evidence A) [8].

A post-hoc analysis of FOURIER published in The Lancet showed that patients who achieved LDL-C below 20 mg/dL had the lowest event rates, with no safety signal at very low LDL levels over the trial duration [9]. This finding supported aggressive LDL lowering and reinforced the benefit-risk profile that underlies Medicare's coverage rationale.

How to Appeal a Medicare Advantage Denial of Repatha

Denials happen. When a Medicare Advantage plan refuses Repatha coverage, the beneficiary has structured appeal rights mandated by CMS [10].

The first level is a plan redetermination. The beneficiary or prescriber submits a written request within 60 days of the denial notice (or 72 hours for an expedited request if the standard timeline could cause serious harm). Include updated labs, a letter of medical necessity specifying why alternatives are inadequate, and documentation of completed step therapy.

The American College of Cardiology's 2019 PCSK9 Inhibitor Prior Authorization Toolkit recommends including the following in appeals: pre-treatment LDL-C, current LDL-C on maximally tolerated therapy, calculated 10-year ASCVD risk score, and a citation to the AHA/ACC guideline recommendation [8].

If the plan upholds its denial, the case automatically advances to an Independent Review Entity (IRE). For Medicare Part D, this is currently MAXIMUS Federal Services. The IRE reviews de novo and is not bound by the plan's determination. CMS data from 2023 show that 42% of Part D IRE appeals resulted in full or partial reversal of the plan's initial denial [10].

Beyond the IRE, further appeal levels include an Administrative Law Judge hearing (if the amount in controversy exceeds $190 for 2025), the Medicare Appeals Council, and federal district court. Most Repatha appeals resolve at the IRE level.

One critical procedural point: if the prescriber requests an expedited coverage determination and the plan denies it, the plan must forward the case to the IRE within 24 hours. This accelerated timeline protects patients with very high LDL-C and recent cardiovascular events.

Repatha vs. Praluent (Alirocumab) on Medicare Advantage

Both PCSK9 inhibitors carry similar Medicare coverage criteria, but formulary preference varies by plan. Alirocumab (Praluent) demonstrated comparable LDL reduction and cardiovascular benefit in the ODYSSEY Outcomes trial (N=18,924), which showed a 15% reduction in major cardiovascular events over 2.8 years of follow-up [11].

Some Medicare Advantage plans designate one PCSK9 inhibitor as preferred over the other, resulting in lower coinsurance. Beneficiaries should check their plan's formulary during open enrollment (October 15 through December 7) or upon a qualifying life event. The Medicare Plan Finder tool at medicare.gov allows drug-specific formulary searches by zip code.

Clinically, both drugs produce approximately 60% LDL-C reduction from baseline. Evolocumab is available in 140 mg every 2 weeks or 420 mg monthly dosing. Alirocumab offers 75 mg or 150 mg every 2 weeks. The monthly dosing option for evolocumab may improve adherence for some patients.

Inclisiran: A Newer Alternative With Different Medicare Coverage

Inclisiran (Leqvio), a small interfering RNA targeting PCSK9 synthesis, received FDA approval in December 2021 and offers twice-yearly dosing after two initial doses [12]. Its Medicare coverage pathway differs from Repatha because inclisiran is administered by a healthcare professional in a clinical setting, making it coverable under Part B (medical benefit) rather than Part D.

Part B coverage of inclisiran means 20% coinsurance after the Part B deductible ($257 in 2025), with no coverage gap or specialty tier considerations. For beneficiaries with supplemental coverage (Medigap), the 20% coinsurance may be covered entirely. This creates a potential cost advantage over Part D PCSK9 inhibitors, though access depends on whether the administering provider accepts Medicare assignment.

The ORION-10 trial showed inclisiran reduced LDL-C by 52% at day 510 vs. placebo in patients with ASCVD (N=1,561, P<0.001) [12]. Cardiovascular outcomes data from the ORION-4 trial (N=15,000) are expected to report in 2026.

Tips for Maximizing Coverage Approval

Physicians and patients can take several concrete steps to improve the probability of first-pass prior authorization approval for Repatha on Medicare Advantage.

First, document statin intolerance rigorously. A note stating "patient cannot tolerate statins" is insufficient. Include the specific statin name, dose, start date, adverse effect experienced, date of discontinuation, and whether rechallenge was attempted. The National Lipid Association defines statin intolerance as inability to tolerate at least two statins (one at the lowest starting dose) due to muscle symptoms that resolved upon discontinuation [4].

Second, obtain the fasting lipid panel close to the prior authorization submission date. Labs older than 90 days are frequently rejected. Some plans require the panel to be drawn while the patient is on their current maximally tolerated regimen for at least 4 weeks.

Third, if the patient has HeFH, include genetic testing results or a completed Dutch Lipid Network Score sheet (score of 8 or higher = definite FH). Genetic confirmation virtually eliminates the step therapy requirement on most plans because guidelines recognize that statin monotherapy is rarely sufficient in FH [8].

Fourth, use the plan's electronic prior authorization portal when available. CMS mandated electronic prior authorization capability for all MA plans by January 2026, and most large carriers already support it. Electronic submissions have faster turnaround (often 24 to 48 hours vs. 7 to 14 days for fax-based requests).

Repatha 420 mg monthly dosing (using the Pushtronex system or three 140 mg autoinjectors) counts as the same drug for prior authorization purposes. Switching between every-2-week and monthly dosing does not require a new authorization on most plans.